Kohlberg Kravis Roberts & Co. L.P. Coherus Bio Sciences, Inc. Transaction History
Kohlberg Kravis Roberts & Co. L.P.
- $2.53 Billion
- Q2 2025
A detailed history of Kohlberg Kravis Roberts & Co. L.P. transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Kohlberg Kravis Roberts & Co. L.P. holds 3,036,076 shares of CHRS stock, worth $5.43 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
3,036,076
Previous 3,036,076
-0.0%
Holding current value
$5.43 Million
Previous $2.46 Million
9.88%
% of portfolio
0.09%
Previous 0.11%
Shares
2 transactions
Others Institutions Holding CHRS
# of Institutions
122Shares Held
57.9MCall Options Held
89.3KPut Options Held
31K-
Black Rock Inc. New York, NY11.8MShares$21 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.6MShares$18.9 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA5.1MShares$9.12 Million0.22% of portfolio
-
Geode Capital Management, LLC Boston, MA2.68MShares$4.79 Million0.0% of portfolio
-
Cm Management, LLC2.25MShares$4.03 Million1.68% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $139M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...